CagriSema Beats Tirzepatide in Diabetes, but Novo’s FDA Decision Is for Obesity
Novo’s phase 3 result beats tirzepatide’s 5 mg dose in type 2 diabetes. The FDA decision due this quarter is for weight management, where CagriSema trailed higher-dose tirzepatide.
CagriSema’s new win came in type 2 diabetes, an indication Novo Nordisk has not filed in the U.S. Its pending U.S. application is for weight management, the indication in which tirzepatide beat it head to head. In REIMAGINE 5, CagriSema produced 12.4% estimated average weight loss against 9.1% for tirzepatide 5 mg in adults with type 2 diabetes, and HbA1c reduction was non-inferior. The 3.3-point gap, measured at week 60 of a 68-week study, is a clear margin. What is narrow is the comparator: 5 mg is the lowest of tirzepatide’s three maintenance doses. Novo’s September 21 release reports the trial.
The obesity comparison points the other way. In the 84-week REDEFINE 4 head-to-head trial, CagriSema produced 23% weight loss against tirzepatide’s 25.5% and missed the primary non-inferiority endpoint. The populations and durations differ, so the two trials are not one contest, but together they define the scope of the new win: CagriSema beat a low tirzepatide dose in diabetes, not higher-dose tirzepatide in obesity. Novo’s February results give the comparison.
The regulatory calendar puts obesity first. Novo submitted CagriSema to the FDA for weight management in December 2025, based on REDEFINE 1 and 2, and has said a decision is expected in the fourth quarter of 2026. The desk expects approval by year-end, since the filing rests on placebo-controlled trials that met their endpoints; REDEFINE 4 bears on market position, not approvability. At launch, CagriSema would enter a weight-management market where the direct comparison favours its main rival.
Diabetes is the later and less certain route. REIMAGINE 1 to 3 met their primary endpoints at the American Diabetes Association meeting in June, and REIMAGINE 5 now adds a head-to-head win. Novo says it will approach regulators to discuss the pathway for a type 2 diabetes indication, but it has not announced a filing date. The company announcement confirms the weight-management submission. REIMAGINE 5 enrolled about 1,000 adults whose diabetes was inadequately controlled on metformin, an SGLT2 inhibitor or both, which is the population a diabetes label would target. Until Novo files, the win supports medical-conference positioning and prescriber interest more than a U.S. label.
The practical reading for the next quarter is that REIMAGINE 5 gives Novo a head-to-head win to cite, but the win sits in the market it cannot yet sell into. Safety, tolerability and the full data will decide how far clinicians extend it.